Omnicell (NASDAQ:OMCL) Shares Down 4.1% - Should You Sell?

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) dropped 4.1% during mid-day trading on Monday . The stock traded as low as $27.21 and last traded at $27.51. Approximately 91,701 shares changed hands during trading, a decline of 84% from the average daily volume of 561,881 shares. The stock had previously closed at $28.69.

Analyst Ratings Changes

OMCL has been the topic of several analyst reports. Piper Sandler restated an "overweight" rating on shares of Omnicell in a report on Friday, May 23rd. JPMorgan Chase & Co. cut their target price on Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, March 20th. Benchmark cut their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Saturday, July 12th. Finally, Wells Fargo & Company reaffirmed an "overweight" rating and issued a $37.00 target price (up from $35.00) on shares of Omnicell in a research report on Friday, May 23rd. Three equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Omnicell currently has an average rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Stock Up 0.7%

The company has a market capitalization of $1.31 billion, a PE ratio of 60.81, a price-to-earnings-growth ratio of 8.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.38 and a quick ratio of 1.23. The firm has a 50-day simple moving average of $29.02 and a 200 day simple moving average of $34.41.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 4.60% and a net margin of 1.87%. The business had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same period in the previous year, the company earned $0.03 earnings per share. The company's revenue for the quarter was up 9.5% compared to the same quarter last year. On average, research analysts predict that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue grew its stake in Omnicell by 8.7% in the second quarter. State of Alaska Department of Revenue now owns 27,906 shares of the company's stock worth $819,000 after purchasing an additional 2,242 shares in the last quarter. Accurate Wealth Management LLC grew its stake in Omnicell by 26.9% in the second quarter. Accurate Wealth Management LLC now owns 45,850 shares of the company's stock worth $1,365,000 after purchasing an additional 9,719 shares in the last quarter. GAMMA Investing LLC grew its stake in Omnicell by 37.1% in the second quarter. GAMMA Investing LLC now owns 1,694 shares of the company's stock worth $50,000 after purchasing an additional 458 shares in the last quarter. Inspire Investing LLC grew its stake in Omnicell by 9.2% in the first quarter. Inspire Investing LLC now owns 9,878 shares of the company's stock worth $345,000 after purchasing an additional 834 shares in the last quarter. Finally, Strs Ohio acquired a new position in Omnicell in the first quarter worth about $5,635,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.